Skip to main content

Quebec’s highest court has authorized a class-action suit on behalf of men who took medication for hair loss and then allegedly suffered various problems, including erectile dysfunction.

The defendants are Merck Canada Inc. and Merck Frosst Canada Ltd, which sold the Propecia and Proscar prescription drugs.

Propecia is used mainly to treat baldness, while Proscar is used primarily to treat enlargement of the prostate. Both contain the active ingredient finasteride.

Story continues below advertisement

The lawsuit covers Quebec men who were prescribed one of the two drugs before Nov. 18, 2011, and then allegedly developed problems that lasted even after they stopped using them.

The problems included erectile dysfunction, lower libido levels, ejaculation issues, shrinkage of the genitals and difficulty in having an orgasm.

It is alleged that doctors prescribed Proscar for hair loss.

A lower court nixed the idea of a lawsuit in 2016, but the appeals court ruled Quebec Superior Court imposed too much of a burden on lead plaintiff Camilo Baratto.

The three-judge appeals panel said the lower court, without having to at that stage of the proceedings, took a position on the scientific debate surrounding the medication and its effects.

The high court said the debate must take place, but not at the stage of the authorization.

Mr. Baratto says he started taking Proscar for his baldness in October, 2008, by cutting the pills to bring the dose closer to that of Propecia.

Story continues below advertisement

He states he stopped the medication after one month because he was starting to have side-effects such as a drop in libido, erectile and ejaculation problems, anxiety and depression symptoms.

Mr. Baratto, who says he is still suffering today from some of the secondary effects, acknowledges the potential risks were mentioned on the container but not the fact that they could continue once he stopped taking the drug.

He alleges the two companies changed the wording in Switzerland in 2008, but failed to do so in Canada until November 2011.

Mr. Baratto is seeking at least $100,000 for all his alleged problems.

The amount for those who will join the action has yet to be determined, but $10,000 in punitive damages is being sought for each.

Lawyers at the firm of Trudel Johnston & Lesperance who launched the legal action said they are happy with the Quebec Court of Appeal’s decision on Thursday to authorize the lawsuit but they did not want to comment further.

Story continues below advertisement

In an e-mail on Friday, Merck Canada said it disagrees with the appeals courts' judicial analysis but did not elaborate.

But the company said it intends to use “reliable and scientific medical information” to defend its position that the drugs are innocuous and efficient.

Related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter